223 Participants Needed

LY3200882 for Solid Cancers

Recruiting at 25 trial locations
Age: 18+
Sex: Any
Trial Phase: Phase 1
Sponsor: Eli Lilly and Company
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

The main purpose of this study is to evaluate the safety of the study drug known as LY3200882 in participants with solid tumors.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Who Is on the Research Team?

C1

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

Principal Investigator

Eli Lilly and Company

Are You a Good Fit for This Trial?

This trial is for people with solid tumors who can prove their cancer diagnosis, have good organ function, and are in decent physical shape (ECOG status of 0 or 1). They must be able to take pills. It's not for those with serious heart disease, other severe illnesses, or acute leukemia.

Inclusion Criteria

My organs are functioning well.
My cancer diagnosis was confirmed through lab tests on tissue or fluid samples.
I can swallow pills.
See 1 more

Exclusion Criteria

I do not have serious heart problems.
I do not have acute leukemia.
I do not have a serious illness besides my current condition.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive LY3200882 in combination with other treatments such as Cisplatin, Radiation, or other drugs to evaluate safety

8-12 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • LY3200882
Trial Overview The study is testing the safety of a new drug called LY3200882 on solid tumors. Participants will also receive established cancer treatments like nab-Paclitaxel, radiotherapy, Cisplatin, LY3300054, and Gemcitabine.
How Is the Trial Designed?
8Treatment groups
Experimental Treatment
Group I: LY3200882 Schedule 2 ExpansionExperimental Treatment1 Intervention
Group II: LY3200882 Schedule 2 EscalationExperimental Treatment1 Intervention
Group III: LY3200882 Schedule 1 ExpansionExperimental Treatment1 Intervention
Group IV: LY3200882 Schedule 1 EscalationExperimental Treatment1 Intervention
Group V: LY3200882 + LY3300054Experimental Treatment2 Interventions
Group VI: LY3200882 + Gemcitabine + nab-PaclitaxelExperimental Treatment3 Interventions
Group VII: LY3200882 + Cisplatin + RadiationExperimental Treatment3 Interventions
Group VIII: Japanese Arm LY3200882Experimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Eli Lilly and Company

Lead Sponsor

Trials
2,708
Recruited
3,720,000+
Dr. Daniel Skovronsky profile image

Dr. Daniel Skovronsky

Eli Lilly and Company

Chief Medical Officer since 2018

MD from Harvard Medical School

David A. Ricks profile image

David A. Ricks

Eli Lilly and Company

Chief Executive Officer since 2017

BSc from Purdue University, MBA from Indiana University

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security